Aortic Valve Stenosis
Conditions
Keywords
severe aortic valve stenosis, low gradient, preserved left ventricular ejection fraction, symptomatic patients
Brief summary
According to current European Recommendations on valvular heart disease (VHD), classical severe aortic stenosis (AS) is defined by an aortic valve area (AVA) ≤1 cm2 and indexed AVA ≤0.6 cm2/m2, a mean aortic pressure gradient (MAG) \>40 mmHg, and a maximal aortic velocity \>4 m/sec. Aortic valve replacement (AVR) is recommended (class I indication) in patients with classical severe AS who have any symptoms related to aortic valve disease. In 2007, Hachicha et al. described a particular pattern of severe AS, characterized by an AVA ≤0.6 cm2/m2, low mean pressure aortic gradient (MAG \<40 mmHg), despite the presence of a preserved left ventricular ejection fraction (LVEF ≥50%). This pattern of AS is encountered in nearly 15-25 % of patients who have severe AS. Typically, these patients are elderly subjects, with several comorbidities, a small left ventricular (LV) cavity with pronounced LV concentric remodeling and a restrictive physiology, leading to a decrease in LV stroke volume despite a preserved LVEF. The diagnosis and management of patients with low gradient severe AS and preserved LVEF are often challenging because: 1. the presence of a true severe aortic stenosis should be carefully confirmed by a multi-modality imaging approach; 2. the best therapeutic management (AVR versus conservative strategy) of symptomatic patients with low gradient severe AS and preserved LVEF is not clearly established. In very recently updated European guidelines on the management of VHD, symptomatic patients with low gradient and low flow severe AS and preserved LVEF have only a class IIa-level C indication for AVR. No specific indications are given for the management of symptomatic patients with low gradient and normal flow severe AS. This lack of indications is clearly attributed to a gap in knowledge which requires further investigations to be filled up.
Interventions
PROCEDUREaortic valve replacement
aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
OTHERstrict clinical surveillance
strict clinical surveillance strategy
Sponsors
Rennes University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>18 years 2. Symptomatic and severe AS defined by an effective AVA ≤1 cm² and indexed AVA ≤0.6 cm2/m2 3. LVEF ≥50% 4. MAG \<40 mm Hg (measure confirmed by the multi-window continuous-wave Doppler interrogation and use of Pedoff probe) 5. Confirmation of the presence of severe AS at DSE and MDCT aortic calcium score 6. Feasibility of AVR by surgery or TAVR according to the heart team 7. Signature of an informed consent
Exclusion criteria
1. Uncontrolled atrial of ventricular arrhythmias 2. Patient having a life expectancy \<1 year, independently from their aortic pathology 3. Coronary artery disease necessitating a percutaneous or surgical revascularisation 4. Presence of a concomitant valve disease needing surgical treatment 5. Patient who are included in another research protocol 6. Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman and minor)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time from randomization to first occurrence of any of the components of the composite outcome (adjudicated): all-cause mortality or cardiovascular related hospitalization | during 2 years follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of cardiovascular mortality | 2 years | — |
| rate of cardiovascular related hospitalization | 2 years | — |
| rate of cerebrovascular events | 2 years | — |
| rate of all-cause mortality | 2 years | — |
| NT-proBNP plasma levels | 6, 12, 18 and 24 months | — |
| quality of life score | 6, 12, 18 and 24 months | test EQ-5D |
| walking distance | 6, 12, 18 and 24 months | 6-minute walking test |
Countries
Belgium, France
Outcome results
None listed